Last reviewed · How we verify
De-prescribe beta blocker therapy
This is a clinical deprescribing protocol that guides the gradual discontinuation of beta-blocker medications in patients for whom continued therapy is no longer indicated.
This is a clinical deprescribing protocol that guides the gradual discontinuation of beta-blocker medications in patients for whom continued therapy is no longer indicated. Used for Safe discontinuation of beta-blocker therapy in patients with resolved or changed clinical indications, Reduction of polypharmacy and adverse effects in elderly patients or those with contraindications to beta-blockers.
At a glance
| Generic name | De-prescribe beta blocker therapy |
|---|---|
| Also known as | De-prescription |
| Sponsor | University of Saskatchewan |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
De-prescribing beta blockers involves a structured, evidence-based approach to safely withdraw these medications in patients who may no longer benefit from them or who are at risk of harm from continued use. The protocol typically includes patient assessment, gradual dose reduction to avoid rebound hypertension or tachycardia, and monitoring for adverse effects during the withdrawal process. This is a clinical practice guideline rather than a pharmacological agent.
Approved indications
- Safe discontinuation of beta-blocker therapy in patients with resolved or changed clinical indications
- Reduction of polypharmacy and adverse effects in elderly patients or those with contraindications to beta-blockers
Common side effects
- Rebound hypertension
- Rebound tachycardia
- Angina pectoris exacerbation
Key clinical trials
- Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial). (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- De-prescribe beta blocker therapy CI brief — competitive landscape report
- De-prescribe beta blocker therapy updates RSS · CI watch RSS
- University of Saskatchewan portfolio CI